Pipeline
Insmed is advancing a pipeline to bring potential new treatments to patients with rare and serious diseases who currently have few, if any, treatment options. We are working with a profound sense of urgency to deliver creative applications of science and technology that have the potential to address these unmet needs.
Product Pipeline
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Approved |
-
ARIKAYCE® (Amikacin Liposome Inhalation Suspension)*
Refractory NTM: M. avium complex (MAC) -
ARIKAYCE® (Amikacin Liposome Inhalation Suspension) Lifecycle Management
Front line, maintenance, other non MAC NTM species, e.g. M. abscessus -
Brensocatib (INS1007): DPP1 Inhibitor
Bronchiectasis -
Brensocatib (INS1007): DPP1 Inhibitor
COVID-19 (IIR) -
Treprostinil Palmitil (INS1009): Inhaled Prostanoid
Pulmonary Arterial Hypertension (PAH) -
RV94
Gram-positive infections -
Internal R&D
Various indications -
Corporate Development
* As a condition of accelerated approval, Insmed is collaborating with the FDA on the design of an additional clinical study to support full approval. The study design is currently under discussion with FDA and is proposed to be a randomized, double-blind, placebo-controlled clinical trial to assess and describe the clinical benefit of ARIKAYCE in patients with NTM lung disease caused by MAC.
Contact Us
